​

Zentalis Pharmaceuticals (ZNTL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ZNTL Stock Forecast

Zentalis Pharmaceuticals (ZNTL) stock forecast, based on 12 Wall Street analysts, predicts a 12-month average price target of $21.86, with a high of $55.00 and a low of $4.00. This represents a 1178.36% increase from the last price of $1.71.

- $11 $22 $33 $44 $55 High: $55 Avg: $21.86 Low: $4 Last Closed Price: $1.71

ZNTL Stock Rating

Zentalis Pharmaceuticals stock's rating consensus is Buy, based on 12 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (66.67%), 4 Hold (33.33%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 12 4 8 0 Strong Sell Sell Hold Buy Strong Buy

ZNTL Price Target Upside V Benchmarks

TypeNameUpside
StockZentalis Pharmaceuticals1178.36%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.71$1.71$1.71
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25135--9
Sep, 25135--9
Aug, 25135--9
Jul, 25135--9
Jun, 25136--10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 18, 2024Akash TewariJefferies$6.00$4.3139.21%250.88%
Jun 18, 2024Matthew HarrisonMorgan Stanley$8.00$4.1493.24%367.84%
Jun 18, 2024Bradley CaninoStifel Nicolaus$10.00$5.3985.53%484.80%
Jun 18, 2024Robert DriscollWedbush$4.00$5.70-29.82%133.92%
May 07, 2024Bradley CaninoStifel Nicolaus$32.00$12.43157.44%1771.35%
Nov 14, 2022Wedbush$32.00$22.5641.84%1771.35%
Nov 11, 2022Morgan Stanley$55.00$20.90163.16%3116.37%
Nov 11, 2022Guggenheim$28.00$21.3531.15%1537.43%
Aug 10, 2022Leerink Partners$42.00$30.4138.11%2356.14%
Aug 10, 2022H.C. Wainwright$55.00$30.4180.86%3116.37%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 29, 2025OppenheimerOutperformOutperformhold
Sep 16, 2024Cowen & Co.BuyBuyhold
Sep 16, 2024OppenheimerOutperformOutperformhold
Aug 12, 2024WedbushHoldNeutralupgrade
Jun 20, 2024UBSNeutraldowngrade
Jun 18, 2024JefferiesHolddowngrade
Jun 18, 2024Morgan StanleyEqual-WeightHolddowngrade
Jun 18, 2024Morgan StanleyOverweightEqual-Weightdowngrade
Jun 18, 2024H.C. WainwrightBuyBuyhold
Jun 18, 2024WedbushUnderperformHolddowngrade

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.47$-2.33----
Avg Forecast$-4.41$-2.52$-2.90$-2.57$-2.33$-1.21
High Forecast$-3.93$-2.35$-2.40$-1.00$-1.57$-1.21
Low Forecast$-5.16$-2.72$-3.35$-3.51$-2.95$-1.21
Surprise %1.36%-7.54%----

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$67.42M----
Avg Forecast-$40.62M$2.67M$23.02M$42.76M$175.34M
High Forecast-$40.98M$2.67M$23.02M$42.76M$175.34M
Low Forecast-$40.54M$2.67M$23.02M$42.76M$175.34M
Surprise %-65.99%----

Net Income Forecast

$-350M $-290M $-230M $-170M $-110M $-50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-292.19M$-165.84M----
Avg Forecast$-292.19M$-165.94M$-187.97M$-147.51M$-147.68M$-79.01M
High Forecast$-257.01M$-153.99M$-156.69M$-65.13M$-102.55M$-79.01M
Low Forecast$-337.33M$-177.89M$-219.24M$-229.88M$-192.82M$-79.01M
Surprise %--0.06%----

ZNTL Forecast FAQ

Is Zentalis Pharmaceuticals stock a buy?

Zentalis Pharmaceuticals stock has a consensus rating of Buy, based on 12 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Zentalis Pharmaceuticals is a favorable investment for most analysts.

What is Zentalis Pharmaceuticals's price target?

Zentalis Pharmaceuticals's price target, set by 12 Wall Street analysts, averages $21.86 over the next 12 months. The price target range spans from $4 at the low end to $55 at the high end, suggesting a potential 1178.36% change from the previous closing price of $1.71.

How does Zentalis Pharmaceuticals stock forecast compare to its benchmarks?

Zentalis Pharmaceuticals's stock forecast shows a 1178.36% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Zentalis Pharmaceuticals over the past three months?

  • October 2025: 11.11% Strong Buy, 33.33% Buy, 55.56% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 11.11% Strong Buy, 33.33% Buy, 55.56% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 11.11% Strong Buy, 33.33% Buy, 55.56% Hold, 0% Sell, 0% Strong Sell.

What is Zentalis Pharmaceuticals’s EPS forecast?

Zentalis Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.9, marking a 24.46% increase from the reported $-2.33 in 2024. Estimates for the following years are $-2.57 in 2026, $-2.33 in 2027, and $-1.21 in 2028.

What is Zentalis Pharmaceuticals’s revenue forecast?

Zentalis Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $2.67M, reflecting a -96.04% decrease from the reported $67.42M in 2024. The forecast for 2026 is $23.02M, followed by $42.76M for 2027, and $175.34M for 2028.

What is Zentalis Pharmaceuticals’s net income forecast?

Zentalis Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-188M, representing an 13.34% increase from the reported $-166M in 2024. Projections indicate $-148M in 2026, $-148M in 2027, and $-79.014M in 2028.